mCRPC: Überlebensvorteil durch zusätzliche PARP-Inhibition

Im Focus Onkologie 2026

View at publisher
Authors: Kathrin von Kieseritzky, Susan Schilling
DOI: 10.1007/s15015-026-4502-4
Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy Prostate Cancer Treatment and Research Advanced Breast Cancer Therapies

Publication details

Journal / source
Im Focus Onkologie
Volume
29
Issue
1-2
Pages
50–50
Publication date
1 February 2026
Language
DE